Cargando…

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

OBJECTIVE: To evaluate the effect of different concomitant disease modifying antirheumatic drugs (DMARDs) on the persistence with antitumour necrosis factor (anti-TNF) therapies in patients with rheumatoid arthritis (RA). METHOD: This analysis included 10 396 patients with RA registered with the Bri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soliman, Moetaza M, Ashcroft, Darren M, Watson, Kath D, Lunt, Mark, Symmons, Deborah P M, Hyrich, Kimme L
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Group 2011
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048625/ https://www.ncbi.nlm.nih.gov/pubmed/21330639 http://dx.doi.org/10.1136/ard.2010.139774

Ejemplares similares

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Davies, Rebecca, et al.
Publicado: (2011)

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
por: Verstappen, Suzanne M M, et al.
Publicado: (2011)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2010)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2017)

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register
por: Mercer, Louise K, et al.
Publicado: (2012)

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register
por: Lord, Paul A. C., et al.
Publicado: (2010)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2017)

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2010)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register
por: Verstappen, Suzanne M. M., et al.
Publicado: (2010)

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
por: Kihara, Mari, et al.
Publicado: (2016)

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
por: Dixon, W G, et al.
Publicado: (2009)

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
por: Saad, Amr A, et al.
Publicado: (2009)

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Galloway, J B, et al.
Publicado: (2011)

Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register
por: McErlane, Flora, et al.
Publicado: (2013)

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
por: Galloway, James B, et al.
Publicado: (2013)

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register
por: Fagerli, Karen Minde, et al.
Publicado: (2018)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
por: Galloway, James B., et al.
Publicado: (2011)

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
por: Hyrich, Kimme L., et al.
Publicado: (2009)

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register
por: Fagerli, Karen M, et al.
Publicado: (2019)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
por: Harrison, M J, et al.
Publicado: (2008)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2007)

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register
por: Dixon, W G, et al.
Publicado: (2010)

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
por: Hyrich, Kimme L., et al.
Publicado: (2011)

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
por: Low, Audrey S L, et al.
Publicado: (2017)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis
por: Taylor, Thomas R.P., et al.
Publicado: (2021)

In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register
por: Verstappen, Suzanne M M, et al.
Publicado: (2011)

Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification
por: Lunt, Mark, et al.
Publicado: (2009)

The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register
por: Humphreys, Jennifer H, et al.
Publicado: (2013)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies
por: Saad, Amr A, et al.
Publicado: (2010)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Davies, Rebecca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tg278hbp2bf8l4sspcpfddgtep